Belmar Pharma Solutions

Belmar is a national compounder best known for bioidentical hormone therapy, operating as both a 503A pharmacy and a 503B outsourcing facility. One attribution detail matters for anyone checking FDA records: Belmar’s 503B facilities are listed by their legal entity name, BSO LLC, not “Belmar.”

Facility & accreditation

Belmar describes itself as a national 503A compounding pharmacy and 503B outsourcing facility ^[2]. On the FDA Registered Outsourcing Facilities (503B) list, the matching entries are “BSO LLC, Golden, CO” (initial registration January 24, 2024) and “BSO LLC, Lakewood, CO” (initial registration November 24, 2015) ^[1]; the Belmar↔BSO link is corroborated by matching Colorado cities on both the FDA list and Belmar’s own facility pages. The company’s site lists NABP accreditation, a LegitScript certification, a California sterile license, and Alliance for Pharmacy Compounding membership, and says it serves practices in all 50 states ^[2] — these are the company’s own statements. Independently, we searched ACHC’s PCAB directory for both “Belmar” and “BSO” and found no PCAB accreditation listed ^[3]. LegitScript’s own lookup lists belmarpharmasolutions.com as Certified, website type Pharmacy ^[5]; we did not confirm the NABP accreditation with NABP.

What they compound

A strong bioidentical-hormone (BHRT) focus — hormones, thyroid, hormone pellets — plus weight management and men’s/women’s wellness ^[2]. Named compounded GLP-1 (semaglutide/tirzepatide) product listings were not confirmed from the pages we reviewed.

Regulatory record

Per the FDA 503B list: the Golden, CO (BSO LLC) site was last inspected June 27, 2025, resulting in a Form 483, action status “Open”; the Lakewood, CO (BSO LLC) site was last inspected July 16, 2025, resulting in a Form 483, with an FDA “Regulatory Meeting Held” on March 3, 2026 and a flag indicating a prior compounding-related action in FDA’s history ^[1]. No warning letter is listed for either Colorado site in that table. The FDA did issue a warning letter on March 31, 2023 addressed to Belmar Pharma Solutions and Drug Depot, LLC dba APS Pharmacy, a 503A pharmacy in Palm Harbor, Florida, citing bulk substances not eligible for 503A compounding and bulk bought from unregistered establishments; the FDA posted a close-out letter dated October 11, 2023 ^[4]. It is in our register of warning letters to compounding pharmacies. A Form 483 documents inspection observations, not a final finding; a regulatory meeting is a step FDA uses to discuss corrections. Dated to our review; status can change.

The read

A credible national hormone specialist with real 503B registration and 50-state reach. The two recent 483s and the Lakewood regulatory meeting are the items to track (the 2023 warning letter to its Florida pharmacy is closed out); the BSO-LLC naming is the practical gotcha when you go to verify anything in FDA records.

References

1. FDA — Registered Outsourcing Facilities (503B) list. (accessed 2026-07-01)
2. Belmar Pharma Solutions — official site. (accessed 2026-07-01)
3. ACHC / PCAB accredited-organization directory (searched “Belmar” and “BSO”). (accessed 2026-10-27)
4. FDA — Warning letter, Belmar Pharma Solutions, Drug Depot, LLC dba APS Pharmacy, case 653740, March 31, 2023. (accessed 2026-10-21)
5. LegitScript — website certification status, belmarpharmasolutions.com: Certified. (accessed 2026-10-27)